RT @CochraneJapan: インターロイキン-6(身体の免疫系が過剰に反応する際に関与するタンパク質)を阻害する薬は新型コロナウイルス感染症の治療薬として有効か? https://t.co/6N3kRDsE7x
インターロイキン-6(身体の免疫系が過剰に反応する際に関与するタンパク質)を阻害する薬は新型コロナウイルス感染症の治療薬として有効か? https://t.co/6N3kRDsE7x
Der Living Systematic Review “Interleukin‐6‐Hemmer zur Behandlung von COVID‐19” kommt erneut zu dem Schluss, dass Tocilizumab die Sterblichkeit bei hospitalisierten Patienten leicht senken kann. Mehr: https://t.co/6gmiOk12Lg
RT @CochraneFrance: 🔝Antagonistes de l'interleukine-6 dans le traitement de la #COVID19 📚Revue @Cochrane_ACE @CovidNma mise à jour évaluan…
RT @CochraneFrance: 🔝Antagonistes de l'interleukine-6 dans le traitement de la #COVID19 📚Revue @Cochrane_ACE @CovidNma mise à jour évaluan…
RT @CochraneFrance: 🔝Antagonistes de l'interleukine-6 dans le traitement de la #COVID19 📚Revue @Cochrane_ACE @CovidNma mise à jour évaluan…
🔝Antagonistes de l'interleukine-6 dans le traitement de la #COVID19 📚Revue @Cochrane_ACE @CovidNma mise à jour évaluant 32 études portant sur 12 160 personnes ➡️Résumé disponible sur @CochraneLibrary 🔗https://t.co/YVtx0AbxBR https://t.co/Zn0ncjykLU
Interleukin-6 blocking agents for treating COVID-19: a living systematic review https://t.co/4KCsw1HAbD
🆕 Updated: Beneficial effect of tocilizumab on all‐cause mortality in the short term in hospitalized people with #COVID19. This living systematic review used L·OVE (Living OVerview of Evidence) by #Epistemonikos to identify studies, among other sources. h
RT @IsabelleBoutron: The @CovidNma living review dedicated to IL6 has been updated and just published in the Cochrane Library https://t.co/…
RT @IsabelleBoutron: The @CovidNma living review dedicated to IL6 has been updated and just published in the Cochrane Library https://t.co/…
RT @IsabelleBoutron: The @CovidNma living review dedicated to IL6 has been updated and just published in the Cochrane Library https://t.co/…
France has 21 pro-Actemra COVID-19 studies and 1 pro-Actemra COVID-19 meta-analysis (Klopfenstein). In the past, Lina Ghosn put too much weight on anti-Actemra studies but in this meta, she just barely qualifies as pro-Actemra. France's 2nd, world's 58th
RT @CRESS_U1153: Read the update of the @CovidNma living review dedicated to IL6 https://t.co/00QKZvGEE8… @cochranecollab @CochraneFrance @…
RT @CRESS_U1153: Read the update of the @CovidNma living review dedicated to IL6 https://t.co/00QKZvGEE8… @cochranecollab @CochraneFrance @…
Read the update of the @CovidNma living review dedicated to IL6 https://t.co/00QKZvGEE8… @cochranecollab @CochraneFrance @CRESS_U1153 @Inserm @INRAE_France @univ_paris_cite @univ_spn https://t.co/p1OAKsQNC8
RT @IsabelleBoutron: The @CovidNma living review dedicated to IL6 has been updated and just published in the Cochrane Library https://t.co/…
The @CovidNma living review dedicated to IL6 has been updated and just published in the Cochrane Library https://t.co/mI7ZKNw8R5 @cochranecollab @CochraneFrance @CRESS_U1153 @Inserm @INRAE_France @univ_paris_cite @univ_spn